Dopamine system genes and ADHD: A review of the evidence

Future Neurology

Volumn 3, Issue 6, 2008, Pages 705-728

  Barr, Cathy L ^a   Misener, Virginia L ^b  

^a TORONTO WESTERN HOSPITAL   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

ADHD; Animal models; Association; Dopamine; Dopamine receptors; Genes; Genetics; Hyperactivity; Impulsivity; Inattention

Indexed keywords

DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; DOPAMINE TRANSPORTER; NEUROTRANSMITTER; PSYCHOSTIMULANT AGENT; SYNAPTOBREVIN 2; SYNAPTOTAGMIN I; SYNTAXIN 1A; VESICULAR MONOAMINE TRANSPORTER 2;

ATTENTION DEFICIT DISORDER; DOPAMINE METABOLISM; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC CODE; GENETIC IDENTIFICATION; GENETIC POLYMORPHISM; GENETIC REGULATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; NEUROTRANSMITTER RELEASE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; SIGNAL TRANSDUCTION; TRANSGENE;

EID: 67149144299     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.3.6.705     Document Type: Review

References (300)

1. Szatmari P, Offord DR, Boyle MH: Ontario Child Health Study: prevalence of attention deficit disorder with hyperactivity. J. Child Psychol. Psychiatry 30, 219-230 (1989).
2. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. American Psychiatric Association. Washington DC, USA (1994).
3. Biederman J, Mick E, Faraone SV: Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. Am. J. Psychiatry 157, 816-818 (2000).
4. Hart EL, Lahey BB, Loeber R, Applegate B, Frick PJ: Developmental change in attention-deficit hyperactivity disorder in boys: a four-year longitudinal study. J. Abnorm. Child Psychol. 23, 729-749 (1995).
5. Barkley RA, Fischer M, Smallish L, Fletcher K: The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J. Abnorm. Psychol. 111, 279-289 (2002).
6. Stein MA, McGough JJ: The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy. Child Adolesc. Psychiatr. Clin. N. Am. 17, 475-490 (2008).
7. Polanczyk G, Zeni C, Genro JP, Roman T, Hutz MH, Rohde LA: Attention-deficit/hyperactivity disorder: advancing on Pharmacogenomics. Pharmacogenomics 6, 225-234 (2005).
8. Levy F: What do dopamine transporter and catechol-O-methyltransferase tell us about attention deficit-hyperactivity disorder? Pharmacogenomic implications. Aust. NZ J. Psychiatry 41, 10-16 (2007).
9. Thapar A, Hervas A, McGuffin P: Childhood hyperactivity scores are highly heritable and show sibling competition effects: twin study evidence. Behav. Genet. 25, 537-544 (1995).
10. Gjone H, Stevenson J, Sundet JM: Genetic influence on parent-reported attention-related problems in a Norwegian general population twin sample. J. Am. Acad. Child. Adolesc. Psychiatry 35, 588-596; discussion 596-598 (1996).
11. Levy F, Hay DA, McStephen M, Wood C, Waldman I: Attention-deficit hyperactivity disorder: a category or a continuum? Genetic analysis of a large-scale twin study. J. Am. Acad. Child. Adolesc. Psychiatry 36, 737-744 (1997).
12. Sherman DK, Iacono WG, McGue MK: Attention-deficit hyperactivity disorder dimensions: a twin study of inattention and impulsivity-hyperactivity. J. Am. Acad. Child. Adolesc. Psychiatry 36, 745-753 (1997).
13. Eaves LJ, Silberg JL, Meyer JM et al.: Genetics and developmental psychopathology: 2. The main effects of genes and environment on behavioral problems in the Virginia Twin Study of Adolescent Behavioral Development. J. Child Psychol. Psychiatry 38, 965-980 (1997).
14. Thapar A, Harrington R, Ross K, McGuffin P: Does the definition of ADHD affect heritability? J. Am. Acad. Child. Adolesc. Psychiatry 39, 1528-1536 (2000).
15. Levy F, McStephen M, Hay DA: The diagnostic genetics of ADHD symptoms and subtypes. In: Attention, Genes and ADHD. Levy F, Hay D (Eds). Brunner-Routledge, Hove, UK, 35-57 (2001).
16. Rasmussen ER, Neuman RJ, Heath AC, Levy F, Hay DA, Todd RD: Replication of the latent class structure of attention-deficit/hyperactivity disorder (ADHD) subtypes in a sample of Australian twins. J. Child Psychol. Psychiatry 43, 1018-1028 (2002).
17. Todd RD, Rasmussen ER, Neuman RJ et al.: Familiality and heritability of subtypes of attention deficit hyperactivity disorder in a population sample of adolescent female twins. Am. J. Psychiatry 158, 1891-1898 (2001).
18. Larsson JO, Larsson H, Lichtenstein P: Genetic and environmental contributions to stability and change of ADHD symptoms between 8 and 13 years of age: a longitudinal twin study. J. Am. Acad. Child. Adolesc. Psychiatry 43, 1267-1275 (2004).
19. Pick LH, Halperin JM, Schwartz ST, Newcorn JH: A longitudinal study of neurobiological mechanisms in boys with attention-deficit hyperactivity disorder: preliminary findings. Biol. Psychiatry 45, 371-373 (1999).
20. 2 receptors on human blood platelets. Psychopharmacology (Berl.) 108, 210-212 (1992).
21. Meng SZ, Ozawa Y, Itoh M, Takashima S: Developmental and age-related changes of dopamine transporter, and dopamine D1 and D2 receptors in human basal ganglia. Brain Res. 843, 136-144 (1999).
22. Levy F, Hay DA, Bennett KS, McStephen M: Gender differences in ADHD subtype comorbidity. J. Am. Acad. Child. Adolesc. Psychiatry. 44, 368-376 (2005).
23. Biederman J, Faraone SV, Monuteaux MC: Differential effect of environmental adversity by gender: Rutter's index of adversity in a group of boys and girls with and without ADHD. Am. J. Psychiatry 159, 1556-1562 (2002).
24. Price TS, Simonoff E, Waldman I, Asherson P, Plomin R: Hyperactivity in preschool children is highly heritable. J. Am. Acad. Child. Adolesc. Psychiatry 40, 1362-1364 (2001).
25. Hudziak JJ, Derks EM, Althoff RR, Rettew DC, Boomsma DI: The genetic and environmental contributions to attention deficit hyperactivity disorder as measured by the Conners' Rating Scales - Revised. Am. J. Psychiatry 162, 1614-1620 (2005).
26. Rietveld MJ, Hudziak JJ, Bartels M, van Beijsterveldt CE, Boomsma DI: Heritability of attention problems in children: longitudinal results from a study of twins, age 3 to 12. J. Child Psychol. Psychiatry 45, 577-588 (2004).
27. Kuntsi J, Rijsdijk F, Ronald A, Asherson P, Plomin R: Genetic influences on the stability of attention-deficit/hyperactivity disorder symptoms from early to middle childhood. Biol. Psychiatry 57, 647-654 (2005).
28. McLoughlin G, Ronald A, Kuntsi J, Asherson P, Plomin R: Genetic support for the dual nature of attention deficit hyperactivity disorder: substantial genetic overlap between the inattentive and hyperactive-impulsive components. J. Abnorm. Child Psychol. 35, 1999-1008 (2007).
29. Dluzen DE: Neuroprotective effects of estrogen upon the nigrostriatal dopaminergic system. J. Neurocytol. 29, 387-399 (2000).
30. Zhou W, Cunningham KA, Thomas ML: Estrogen regulation of gene expression in the brain: a possible mechanism altering the response to psychostimulants in female rats. Brain Res. Mol. Brain Res. 100, 75-83 (2002).
31. McEwen BS, Alves SE: Estrogen actions in the central nervous system. Endocr. Rev. 20, 279-307 (1999).
32. Lee SH, Mouradian MM: Up-regulation of D1A dopamine receptor gene transcription by estrogen. Mol. Cell. Endocrinol. 156, 151-157 (1999).
33. Wender PH: Minimal brain dysfunction in children. Wiley-Liss, NY, USA (1971).
34. Levy F, Swanson JM: Timing, space and ADHD: the dopamine theory revisited. Aust. NZ J. Psychiatry 35, 504-511 (2001).
35. Solanto MV: Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav. Brain Res. 130, 65-71 (2002).
36. Solanto MV: Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behav. Brain Res. 94, 127-152 (1998).
37. Levy F: The dopamine theory of attention deficit hyperactivity disorder (ADHD). Aust. NZ J. Psychiatry 25, 277-283 (1991).
38. van der Kooij MA, Glennon JC: Animal models concerning the role of dopamine in attention-deficit hyperactivity disorder. Neurosci. Biobehav. Rev. 31, 597-618 (2007).
39. Volkow ND, Wang GJ, Fowler JS, Ding YS: Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. Biol. Psychiatry 57, 1410-1415 (2005).
40. Swanson JM, Kinsbourne M, Nigg J et al.: Etiologic subtypes of attention-deficit/hyperactivity disorder: brain imaging, molecular genetic and environmental factors and the dopamine hypothesis. Neuropsychol. Rev. 17, 39-59 (2007).
41. Seeman P, Madras BK: Anti-hyperactivity medication: methylphenidate and amphetamine. Mol. Psychiatry 3, 386-396 (1998).
42. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG: Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 379, 606-612 (1996).
43. Clifford JJ, Tighe O, Croke DT, Sibley DR, Drago J, Waddington JL: Topographical evaluation of the phenotype of spontaneous behaviour in mice with targeted gene deletion of the D1A dopamine receptor: paradoxical elevation of grooming syntax. Neuropharmacology 37, 1595-1602 (1998).
44. Xu M, Moratalla R, Gold LH et al.: Dopamine D1 receptor mutant mice are deficient in striatal expression of dynorphin and in dopamine-mediated behavioral responses. Cell 79, 729-742 (1994).
45. Xu M, Hu XT, Cooper DC et al.: Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1 receptor mutant mice. Cell 79, 945-955 (1994).
46. Avale ME, Falzone TL, Gelman DM, Low MJ, Grandy DK, Rubinstein M: The dopamine D4 receptor is essential for hyperactivity and impaired behavioral inhibition in a mouse model of attention deficit/ hyperactivity disorder. Mol. Psychiatry 9, 718-726 (2004).
47. Mill J: Rodent models: utility for candidate gene studies in human attention-deficit hyperactivity disorder (ADHD). J. Neurosci. Methods 166, 294-305 (2007).
48. Quist JF, Kennedy JL: Genetics of childhood disorders: XXIII. ADHD, part 7: the serotonin system. J. Am. Acad. Child. Adolesc. Psychiatry 40, 253-256 (2001).
49. Arnsten AF: Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J. Clin. Psychiatry 8(Suppl. 67), 7-12 (2006).
50. Carlsson ML: On the role of prefrontal cortex glutamate for the antithetical phenomenology of obsessive compulsive disorder and attention deficit hyperactivity disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 25, 5-26 (2001).
51. Oades RD: Dopamine may be 'hyper' with respect to noradrenaline metabolism, but 'hypo' with respect to serotonin metabolism in children with attention-deficit hyperactivity disorder. Behav. Brain Res. 130, 97-102 (2002).
52. Sagvolden T, Russell VA, Aase H, Johansen EB, Farshbaf M: Rodent models of attention-deficit/hyperactivity disorder. Biol. Psychiatry 57, 1239-1247 (2005).
53. Russell VA: Reprint of 'Neurobiology of animal models of attention-deficit hyperactivity disorder. J. Neurosci. Methods 166, I-XIV (2007).
54. Zhuang X, Oosting RS, Jones SR et al.: Hyperactivity and impaired response habituation in hyperdopaminergic mice. Proc. Natl Acad. Sci. USA 98, 1982-1987 (2001).
55. Belluscio L, Gold GH, Nemes A, Axel R: Mice deficient in G(olf) are anosmic. Neuron 20, 69-81 (1998).
56. Hess EJ, Collins KA, Wilson MC: Mouse model of hyperkinesis implicates SNAP-25 in behavioral regulation. J. Neurosci. 16, 3104-3111 (1996).
57. Bajjalieh SM, Scheller RH: The biochemistry of neurotransmitter secretion. J. Biol. Chem. 270, 1971-1974 (1995).
58. Heyser CJ, Wilson MC, Gold LH: Coloboma hyperactive mutant exhibits delayed neurobehavioral developmental milestones. Brain Res. Dev. Brain Res. 89, 264-269 (1995).
59. Martin NC, Piek JP, Hay D: DCD and ADHD: a genetic study of their shared aetiology. Hum. Mov. Sci. 25, 110-124 (2006).
60. Piek JP, Pitcher TM, Hay DA: Motor coordination and kinaesthesis in boys with attention deficit-hyperactivity disorder. Dev. Med. Child Neurol. 41, 159-165 (1999).
61. Trantham-Davidson H, Vazdarjanova A, Dai R, Terry A, Bergson C: Up-regulation of calcyon results in locomotor hyperactivity and reduced anxiety in mice. Behav. Brain Res. 189, 244-249 (2008).
62. Heijtz RD, Alexeyenko A, Castellanos FX: Calcyon mRNA expression in the frontal-striatal circuitry and its relationship to vesicular processes and ADHD. Behav. Brain Funct. 3, 33 (2007).
63. Xiao J, Dai R, Negyessy L, Bergson C: Calcyon, a novel partner of clathrin light chain, stimulates clathrin-mediated endocytosis. J. Biol. Chem. 281, 15182-15193 (2006).
64. Gainetdinov RR, Mohn AR, Bohn LM, Caron MG: Glutamatergic modulation of hyperactivity in mice lacking the dopamine transporter. Proc. Natl Acad. Sci. USA 98, 11047-11054 (2001).
65. Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG: Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 283, 397-401 (1999).
66. Cook EH Jr, Stein MA, Krasowski MD et al.: Association of attention-deficit disorder and the dopamine transporter gene. Am. J. Hum. Genet. 56, 993-998 (1995).
67. Daly G, Hawi Z, Fitzgerald M, Gill M: Mapping susceptibility loci in attention deficit hyperactivity disorder: preferential transmission of parental alleles at DAT1, DBH and DRD5 to affected children. Mol. Psychiatry 4, 192-196 (1999).
68. Gill M, Daly G, Heron S, Hawi Z, Fitzgerald M: Confirmation of association between attention deficit hyperactivity disorder and a dopamine transporter polymorphism. Mol. Psychiatry 2, 311-313 (1997).
69. Waldman ID, Rowe DC, Abramowitz A et al.: Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: heterogeneity owing to diagnostic subtype and severity. Am. J. Hum. Genet. 63, 1767-1776 (1998).
70. Curran S, Mill J, Tahir E et al.: Association study of a dopamine transporter polymorphism and attention deficit hyperactivity disorder in UK and Turkish samples. Mol. Psychiatry 6, 425-428 (2001).
71. Chen CK, Chen SL, Mill J et al.: The dopamine transporter gene is associated with attention deficit hyperactivity disorder in a Taiwanese sample. Mol. Psychiatry 8, 393-396 (2003).
72. Brookes KJ, Mill J, Guindalini C et al.: A common haplotype of the dopamine transporter gene associated with attention-deficit/ hyperactivity disorder and interacting with maternal use of alcohol during pregnancy. Arch. Gen. Psychiatry 63, 74-81 (2006).
73. Lim MH, Kim HW, Paik KC, Cho SC, Yoon DY, Lee HJ: Association of the DAT1 polymorphism with attention deficit hyperactivity disorder (ADHD): a family-based approach. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141, 309-311 (2006).
74. Holmes J, Payton A, Barrett JH et al.: A family-based and case-control association study of the dopamine D4 receptor gene and dopamine transporter gene in attention deficit hyperactivity disorder. Mol. Psychiatry 5, 523-530 (2000).
75. Palmer CG, Bailey JN, Ramsey C et al.: No evidence of linkage or linkage disequilibrium between DAT1 and attention deficit hyperactivity disorder in a large sample. Psychiatr. Genet. 9, 157-160 (1999).
76. Todd RD Jong YJ, Lobos EA, Reich W, Heath AC, Neuman RJ: No association of the dopamine transporter gene 3′ VNTR polymorphism with ADHD subtypes in a population sample of twins. Am. J. Med. Genet. 105, 745-748 (2001).
77. Muglia P, Jain U, Inkster B, Kennedy JL: A quantitative trait locus analysis of the dopamine transporter gene in adults with ADHD. Neuropsychopharmacology 27, 655-662 (2002).
78. Roman T, Schmitz M, Polanczyk G, Eizirik M, Rohde LA, Hutz MH: Attention-deficit hyperactivity disorder: a study of association with both the dopamine transporter gene and the dopamine D4 receptor gene. Am. J. Med. Genet. 105, 471-478 (2001).
79. Smith KM, Daly M, Fischer M et al.: Association of the dopamine β hydroxylase gene with attention deficit hyperactivity disorder: genetic analysis of the Milwaukee longitudinal study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 119, 77-85 (2003).
80. Kim YS, Leventhal BL, Kim SJ et al.: Family-based association study of DAT1 and DRD4 polymorphism in Korean children with ADHD. Neurosci. Lett. 390, 176-181 (2005).
81. Langley K, Turic D, Peirce TR et al.: No support for association between the dopamine transporter (DAT1) gene and ADHD. Am. J. Med. Genet. B Neuropsychiatr. Genet. 139, 7-10 (2005).
82. Cheuk DK, Li SY, Wong V: No association between VNTR polymorphisms of dopamine transporter gene and attention deficit hyperactivity disorder in Chinese children. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141, 123-125 (2006).
83. Simsek M, Al-Sharbati M, Al-Adawi S, Ganguly SS, Lawatia K: Association of the risk allele of dopamine transporter gene (DAT1*10) in Omani male children with attention-deficit hyperactivity disorder. Clin. Biochem. 38, 739-742 (2005).
84. Qian Q, Wang Y, Zhou R, Yang L, Faraone SV: Family based and case-control association studies of DRD4 and DAT1 polymorphisms in Chinese attention deficit hyperactivity disorder patients suggest long repeats contribute to genetic risk for the disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 128, 84-89 (2004).
85. Simsek M, Al-Sharbati M, Al-Adawi S, Lawatia K: The VNTR polymorphism in the human dopamine transporter gene: improved detection and absence of association of VNTR alleles with attention-deficit hyperactivity disorder. Genet. Test 10, 31-34 (2006).
86. Bakker SC, van der Meulen EM, Oteman N et al.: DAT1, DRD4, and DRD5 polymorphisms are not associated with ADHD in Dutch families. Am. J. Med. Genet. B Neuropsychiatr. Genet. 132, 50-52 (2005).
87. Das M, Mukhopadhyay K: DAT1 3′-UTR 9allele R: preferential transmission in Indian children with attention deficit hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144, 826-829 (2007).
88. Genro JP, Zeni C, Polanczyk GV, Roman T, Rohde LA, Hutz MH: A promoter polymorphism (-839 C > T) at the dopamine transporter gene is associated with attention deficit/hyperactivity disorder in Brazilian children. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144, 215-219 (2007).
89. Barr CL, Xu C, Kroft J et al.: Haplotype study of three polymorphisms at the dopamine transporter locus confirm linkage to attention-deficit/hyperactivity disorder. Biol. Psychiatry 49, 333-339 (2001).
90. Bobb AJ, Addington AM, Sidransky E et al.: Support for association between ADHD and two candidate genes: NET1 and DRD1. Am. J. Med. Genet. B Neuropsychiatr. Genet. 134, 67-72 (2005).
91. Kustanovich V, Ishii J, Crawford L et al.: Transmission disequilibrium testing of dopamine-related candidate gene polymorphisms in ADHD: confirmation of association of ADHD with DRD4 and DRD5. Mol. Psychiatry 9, 711-717 (2004).
92. Banoei MM, Majidizadeh T, Shirazi E et al.: No association between the DAT1 10-repeat allele and ADHD in the Iranian population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147B, 110-111 (2008).
93. Johansson S, Halleland H, Halmoy A et al.: Genetic analyses of dopamine related genes in adult ADHD patients suggest an association with the DRD5-microsatellite repeat, but not with DRD4 or SLC6A3 VNTRs. Am. J. Med. Genet. B Neuropsychiatr. Genet. DOI: 10.1002/ ajmg.b.30662 (2007).
94. Nyman ES, Ogdie MN, Loukola A et al.: ADHD candidate gene study in a population-based birth cohort: association with DBH and DRD2. J. Am. Acad. Child. Adolesc. Psychiatry 46, 1614-1621 (2007).
95. Bruggemann D, Sobanski E, Alm B et al.: No association between a common haplotype of the 6 and 10-repeat alleles in intron 8 and the 3′UTR of the DAT1 gene and adult attention deficit hyperactivity disorder. Psychiatr. Genet. 17, 121 (2007).
96. Purper-Ouakil D, Wohl M, Mouren MC, Verpillat P, Ades J, Gorwood P: Meta-analysis of family-based association studies between the dopamine transporter gene and attention deficit hyperactivity disorder. Psychiatr. Genet. 15, 53-59 (2005).
97. Faraone SV, Perlis RH, Doyle AE et al.: Molecular genetics of attention-deficit/hyperactivity disorder. Biol. Psychiatry 57, 1313-1323 (2005).
98. Maher BS, Marazita ML, Ferrell RE, Vanyukov MM: Dopamine system genes and attention deficit hyperactivity disorder: a meta-analysis. Psychiatr. Genet. 12, 207-215 (2002).
99. Yang B, Chan RC, Jing J, Li T, Sham P, Chen RY: A meta-analysis of association studies between the 10-repeat allele of a VNTR polymorphism in the 3′-UTR of dopamine transporter gene and attention deficit hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144, 541-550 (2007).
100. Li D, Sham PC, Owen MJ, He L: Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Hum. Mol. Genet. 15, 2276-2284 (2006).
101. Galili-Weisstub E, Levy S, Frisch A et al.: Dopamine transporter haplotype and attention-deficit hyperactivity disorder. Mol. Psychiatry 10, 617-618 (2005).
102. Hawi Z, Lowe N, Kirley A et al.: Linkage disequilibrium mapping at DAT1, DRD5 and DBH narrows the search for ADHD susceptibility alleles at these loci. Mol. Psychiatry 8, 299-308 (2003).
103. Asherson P, Brookes K, Franke B et al.: Confirmation that a specific haplotype of the dopamine transporter gene is associated with combined-type ADHD. Am. J. Psychiatry 164, 674-677 (2007).
104. Feng Y, Wigg KG, Makkar R et al.: Sequence variation in the 3′-untranslated region of the dopamine transporter gene and attention-deficit hyperactivity disorder (ADHD). Am. J. Med. Genet. B Neuropsychiatr. Genet. 4, 4 (2005).
105. Ouellet-Morin I, Wigg KG, Feng Y et al.: Association of the dopamine transporter gene and ADHD symptoms in a Canadian population-based sample of same-age twins. Am. J. Med. Genet. B Neuropsychiatr. Genet. DOI:10.1002/ajmg.b.30677 (2007).
106. Van Ness SH, Owens MJ, Kilts CD: The variable number of tandem repeats element in DAT1 regulates in vitro dopamine transporter density. BMC Genet. 6, 55 (2005).
107. Guindalini C, Howard M, Haddley K et al.: A dopamine transporter gene functional variant associated with cocaine abuse in a Brazilian sample. Proc. Natl Acad. Sci. USA. 103, 4552-4557 (2006).
108. Ohadi M, Shirazi E, Tehranidoosti M et al.: Attention-deficit/ hyperactivity disorder (ADHD) association with the DAT1 core promoter-67 T allele. Brain Res. 1101, 1-4 (2006).
109. Friedel S, Saar K, Sauer S et al.: Association and linkage of allelic variants of the dopamine transporter gene in ADHD. Mol. Psychiatry. 12, 923-933 (2007).
110. Martinez D, Gelernter J, Abi-Dargham A et al.: The variable number of tandem repeats polymorphism of the dopamine transporter gene is not associated with significant change in dopamine transporter phenotype in humans. Neuropsychopharmacology 24, 553-560 (2001).
111. Heinz A, Goldman D, Jones DW et al.: Genotype influences in vivo dopamine transporter availability in human striatum. Neuropsychopharmacology 22, 133-139 (2000).
112. van Dyck CH, Malison RT, Jacobsen LK et al.: Increased dopamine transporter availability associated with the 9-repeat allele of the SLC6A3 gene. J. Nucl. Med. 46, 745-751 (2005).
113. Winsberg BG, Comings DE: Association of the dopamine transporter gene (DAT1) with poor methylphenidate response. J. Am. Acad. Child. Adolesc. Psychiatry 38, 1474-1477 (1999).
114. Kirley A, Lowe N, Hawi Z et al.: Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am. J. Med. Genet. 121B, 50-54 (2003).
115. Roman T, Szobot C, Martins S, Biederman J, Rohde LA, Hutz MH: Dopamine transporter gene and response to methylphenidate in attention-deficit/ hyperactivity disorder. Pharmacogenetics 12, 497-499 (2002).
116. Kahn RS, Khoury J, Nichols WC, Lanphear BP: Role of dopamine transporter genotype and maternal prenatal smoking in childhood hyperactive-impulsive, inattentive, and oppositional behaviors. J. Pediatr. 143, 104-110 (2003).
117. Fuke S, Suo S, Takahashi N, Koike H, Sasagawa N, Ishiura S: The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics J. 1, 152-156 (2001).
118. Miller GM, Madras BK: Polymorphisms in the 3′-untranslated region of human and monkey dopamine transporter genes affect reporter gene expression. Mol. Psychiatry 7, 44-55 (2002).
119. Mill J, Asherson P, Craig I, D'Souza UM: Transient expression analysis of allelic variants of a VNTR in the dopamine transporter gene (DAT1). BMC Genet. 6, 3 (2005).
120. Greenwood TA, Kelsoe JR: Promoter and intronic variants affect the transcriptional regulation of the human dopamine transporter gene. Genomics 82, 511-520 (2003).
121. Mill J, Asherson P, Browes C, D'Souza U, Craig I: Expression of the dopamine transporter gene is regulated by the 3′ UTR VNTR: evidence from brain and lymphocytes using quantitative RT-PCR. Am. J. Med. Genet. 114, 975-979 (2002).
122. Brookes KJ, Neale BM, Sugden K, Khan N, Asherson P, D'Souza UM: Relationship between VNTR polymorphisms of the human dopamine transporter gene and expression in post-mortem midbrain tissue. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B, 1070-1078 (2007).
123. Spencer TJ, Biederman J, Madras BK et al.: Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane. Biol. Psychiatry 62, 1059-1061 (2007).
124. Spencer TJ, Biederman J, Madras BK et al.: In vivo neuroreceptor imaging in attention-deficit/hyperactivity disorder: a focus on the dopamine transporter. Biol. Psychiatry 57, 1293-1300 (2005).
125. Madras BK, Miller GM, Fischman AJ: The dopamine transporter and attention-deficit/hyperactivity disorder. Biol. Psychiatry 57, 1397-1409 (2005).
126. Krause J: SPECT and PET of the dopamine transporter in attention-deficit/ hyperactivity disorder. Expert Rev. Neurother. 8, 611-625 (2008).
127. Kelada SN, Costa-Mallen P, Checkoway H et al.: Dopamine transporter (SLC6A3) 5′ region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson's disease. Pharmacogenet. Genomics. 15, 659-668 (2005).
128. Van Tol HH, Wu CM, Guan HC et al.: Multiple dopamine D4 receptor variants in the human population. Nature 358, 149-152 (1992).
129. Lichter JB, Barr CL, Kennedy JL, Van Tol HH, Kidd KK, Livak KJ: A hypervariable segment in the human dopamine receptor D4 (DRD4) gene. Hum. Mol. Genet. 2, 767-73. (1993).
130. Asghari V, Schoots O, van Kats S et al.: Dopamine D4 receptor repeat: analysis of different native and mutant forms of the human and rat genes. Mol. Pharmacol. 46, 364-373 (1994).
131. Asghari V, Sanyal S, Buchwaldt S, Paterson A, Jovanovic V, Van Tol HH: Modulation of intracellular cyclic AMP levels by different human dopamine D4 receptor variants. J. Neurochem. 65, 1157-1165 (1995).
132. Jovanovic V, Guan HC, Van Tol HH: Comparative pharmacological and functional analysis of the human dopamine D4.2 and D4.10 receptor variants. Pharmacogenetics 9, 561-568 (1999).
133. Schoots O, Van Tol HH: The human dopamine D4 receptor repeat sequences modulate expression. Pharmacogenomics J. 3, 343-348 (2003).
134. Catalano M, Nobile M, Novelli E, Nothen MM, Smeraldi E: Distribution of a novel mutation in the first exon of the human dopamine D4 receptor gene in psychotic patients. Biol. Psychiatry 34, 459-464 (1993).
135. Nothen MM, Cichon S, Hemmer S et al.: Human dopamine D4 receptor gene: frequent occurrence of a null allele and observation of homozygosity. Hum. Mol. Genet. 3, 2207-2212 (1994).
136. Cichon S, Nothen MM, Catalano M et al.: Identification of two novel polymorphisms and a rare deletion variant in the human dopamine D4 receptor gene. Psychiatr. Genet. 5, 97-103 (1995).
137. Seaman MI, Fisher JB, Chang F, Kidd KK: Tandem duplication polymorphism upstream of the dopamine D4 receptor gene (DRD4). Am. J. Med. Genet. 88, 705-709 (1999).
138. D'Souza UM, Russ C, Tahir E et al.: Functional effects of a tandem duplication polymorphism in the 5′ flanking region of the DRD4 gene. Biol. Psychiatry 56, 691-697 (2004).
139. Kereszturi E, Kiraly O, Csapo Z et al.: Association between the 120-bp duplication of the dopamine D4 receptor gene and attention deficit hyperactivity disorder: genetic and molecular analyses. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144, 231-236 (2007).
140. Okuyama Y, Ishiguro H, Toru M, Arinami T: A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia. Biochem. Biophys. Res. Commun. 258, 292-295 (1999).
141. Kereszturi E, Kiraly O, Barta C, Molnar N, Sasvari-Szekely M, Csapo Z: No direct effect of the -521 C/T polymorphism in the human dopamine D4 receptor gene promoter on transcriptional activity. BMC Mol. Biol. 7, 18 (2006).
142. LaHoste GJ, Swanson JM, Wigal SB et al.: Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. Mol. Psychiatry 1, 121-124 (1996).
143. Swanson JM, Sunohara GA, Kennedy JL et al.: Association of the dopamine receptor D4 (DRD4) gene with a refined phenotype of attention deficit hyperactivity disorder (ADHD): a family based approach. Mol. Psychiatry 3, 38-41 (1998).
144. Sunohara GA, Roberts W, Malone M et al.: Linkage of the dopamine D4 receptor gene and attention-deficit/hyperactivity disorder. J. Am. Acad. Child. Adolesc. Psychiatry 39, 1537-1542 (2000).
145. Faraone SV, Biederman J, Weiffenbach B et al.: Dopamine D4 gene 7-repeat allele and attention deficit hyperactivity disorder. Am. J. Psychiatry 156, 768-770 (1999).
146. Tahir E, Yazgan Y, Cirakoglu B, Ozbay F, Waldman I, Asherson PJ: Association and linkage of DRD4 and DRD5 with attention deficit hyperactivity disorder (ADHD) in a sample of Turkish children. Mol. Psychiatry 5, 396-404 (2000).
147. Smalley SL, Bailey JN, Palmer CG et al.: Evidence that the dopamine D4 receptor is a susceptibility gene in attention deficit hyperactivity disorder. Mol. Psychiatry 3, 427-430 (1998).
148. Rowe DC, Stever C, Giedinghagen LN et al.: Dopamine DRD4 receptor polymorphism and attention deficit hyperactivity disorder. Mol. Psychiatry 3, 419-426 (1998).
149. Mill J, Curran S, Kent L et al.: Attention deficit hyperactivity disorder (ADHD) and the dopamine D4 receptor gene: evidence of association but no linkage in a UK sample. Mol. Psychiatry. 6, 440-444 (2001).
150. Gornick MC, Addington A, Shaw P et al.: Association of the dopamine receptor D4 (DRD4) gene 7-repeat allele with children with attention-deficit/hyperactivity disorder (ADHD): an update. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144, 379-382 (2007).
151. Castellanos FX, Lau E, Tayebi N et al.: Lack of an association between a dopamine-4 receptor polymorphism and attention-deficit/ hyperactivity disorder: genetic and brain morphometric analyses. Mol. Psychiatry 3, 431-434 (1998).
152. Hawi Z, McCarron M, Kirley A, Daly G, Fitzgerald M, Gill M: No association of the dopamine DRD-4 receptor (DRD4) gene polymorphism with attention deficit hyperactivity disorder (ADHD) in the Irish population. Am. J. Med. Genet. 96, 268-272 (2000).
153. Kotler M, Manor I, Sever Y et al.: Failure to replicate an excess of the long dopamine D4 exon III repeat polymorphism in ADHD in a family-based study. Am. J. Med. Genet. 96, 278-281 (2000).
154. Kirley A, Hawi Z, Daly G et al.: Dopaminergic system genes in ADHD: toward a biological hypothesis. Neuropsychopharmacology 27, 607-619 (2002).
155. Eisenberg J, Zohar A, Mei-Tal G et al.: A haplotype relative risk study of the dopamine D4 receptor (DRD4) exon III repeat polymorphism and attention deficit hyperactivity disorder (ADHD). Am. J. Med. Genet. 96, 258-261 (2000).
156. Manor I, Tyano S, Eisenberg J, Bachner-Melman R, Kotler M, Ebstein RP: The short DRD4 repeats confer risk to attention deficit hyperactivity disorder in a family-based design and impair performance on a continuous performance test (TOVA). Mol. Psychiatry. 7, 790-794 (2002).
157. Leung PW, Lee CC, Hung SF et al.: Dopamine receptor D4 (DRD4) gene in Han Chinese children with attention-deficit/ hyperactivity disorder (ADHD): increased prevalence of the 2-repeat allele. Am. J. Med. Genet. B Neuropsychiatr. Genet. 133, 54-56 (2005).
158. Faraone SV, Doyle AE, MickE, Biederman J: Meta-analysis of the association between the 7-repeat allele of the dopamine D(4) receptor gene and attention deficit hyperactivity disorder. Am. J. Psychiatry 158, 1052-1057 (2001).
159. McCracken JT, Smalley SL, McGough JJ et al.: Evidence for linkage of a tandem duplication polymorphism upstream of the dopamine D4 receptor gene (DRD4) with attention deficit hyperactivity disorder (ADHD). Mol. Psychiatry 5, 531-536 (2000).
160. Barr CL, Feng Y, Wigg KG et al.: 5′ untranslated region of the dopamine D4 receptor gene and attention-deficit hyperactivity disorder. Am. J. Med. Genet. 105, 84-90 (2001).
161. Mill J, Fisher N, Curran S, Richards S, Taylor E, Asherson P: Polymorphisms in the dopamine D4 receptor gene and attention-deficit hyperactivity disorder. Neuroreport 14, 1463-1466 (2003).
162. Brookes KJ, Xu X, Chen CK, Huang YS, Wu YY, Asherson P: No evidence for the association of DRD4 with ADHD in a Taiwanese population within-family study. BMC Med. Genet. 6, 31 (2005).
163. Lowe N, Kirley A, Mullins C, Fitzgerald M, Gill M, Hawi Z: Multiple marker analysis at the promoter region of the DRD4 gene and ADHD: evidence of linkage and association with the SNP -616. Am. J. Med. Genet. B Neuropsychiatr. Genet. 131, 33-37 (2004).
164. Todd RD, Neuman RJ, Lobos EA, Jong YJ, Reich W, Heath AC: Lack of association of dopamine D4 receptor gene polymorphisms with ADHD subtypes in a population sample of twins. Am. J. Med. Genet. 105, 432-438 (2001).
165. Payton A, Holmes J, Barrett JH et al.: Examining for association between candidate gene polymorphisms in the dopamine pathway and attention-deficit hyperactivity disorder: a family-based study. Am. J. Med. Genet. 105, 464-470 (2001).
166. Yang JW, Jang WS, Hong SD et al.: A case - control association study of the polymorphism at the promoter region of the DRD4 gene in Korean boys with attention deficit-hyperactivity disorder: evidence of association with the -521 C/T SNP. Prog. Neuropsychopharmacol. Biol. Psychiatry 32, 243-248 (2008).
167. Barr CL, Wigg KG, Bloom S et al.: Further evidence from haplotype analysis for linkage of the dopamine D4 receptor gene and attention-deficit hyperactivtty disorder. Am. J. Med. Genet. 96, 262-267 (2000).
168. Helms CM, Gubner NR, Wilhelm CJ, Mitchell SH, Grandy DK: D(4) receptor deficiency in mice has limited effects on impulsivity and novelty seeking. Pharmacol. Biochem. Behav. 90, 387-393 (2008).
169. Manor I, Corbex M, Eisenberg J et al.: Association of the dopamine D5 receptor with attention deficit hyperactivity disorder (ADHD) and scores on a continuous performance test (TOVA). Am. J. Med. Genet. B Neuropsychiatr. Genet. 127, 73-77 (2004).
170. Barr CL, Wigg KG, Feng Y et al.: Attention-deficit hyperactivity disorder and the gene for the dopamine D5 receptor. Mol. Psychiatry 5, 548-551 (2000).
171. Lowe N, Kirley A, Hawi Z et al.: Joint Analysis of the DRD5 marker concludes association with attention-deficit/hyperactivity disorder confined to the predominantly inattentive and combined subtypes. Am. J. Hum. Genet. 74, 348-356 (2004).
172. Mill J, Curran S, Richards S, Taylor E, Asherson P: Polymorphisms in the dopamine D5 receptor (DRD5) gene and ADHD. Am. J. Med. Genet. B Neuropsychiatr. Genet. 25B, 38-42 (2004).
173. Nguyen T, Bard J, Jin H et al.: Human dopamine D5 receptor pseudogenes. Gene 109, 211-218 (1991).
174. Jackson DM, Westlind-Danielsson A: Dopamine receptors: molecular biology, biochemistry and behavioural aspects. Pharmacol. Ther. 64, 291-370 (1994).
175. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG: Dopamine receptors: from structure to function. Physiol. Rev. 78, 189-225 (1998).
176. Misener V, Luca P, Azeke O et al.: Linkage of the dopamine receptor D1 gene to attention-deficit/hyperactivity disorder. Mol. Psychiatry9, 500-509 (2004).
177. Luca P, Laurin N, Misener VL et al.: Association of the dopamine receptor D1 gene, DRD1, with inattention symptoms in families selected for reading problems. Mol. Psychiatry 12, 776-785 (2007).
178. Huang W, Ma JZ, Payne TJ, Beuten J, Dupont RT, Li MD: Significant association of DRD1 with nicotine dependence. Hum. Genet. 123, 133-140 (2008).
179. Comings DE, Comings BG, Muhleman D et al.: The dopamine D2 receptor locus as a modifying gene in neuropsychiatric disorders. JAMA 266, 1793-1800 (1991).
180. Neville MJ, Johnstone EC, Walton RT: Identification and characterization of ANKK1: a novel kinase gene closely linked to DRD2 on chromosome band 11q23.1. Hum. Mutat. 23, 540-545 (2004).
181. Rowe DC, Van den Oord EJ, Stever C et al.: The DRD2 TaqI polymorphism and symptoms of attention deficit hyperactivity disorder. Mol. Psychiatry 4, 580-586 (1999).
182. Waldman ID, Robinson BF, Rhee SH: A logistic regression extension of the transmission disequilibrium test for continuous traits: application to linkage disequilibrium between alcoholism and the candidate genes DRD2 and ADH3. Genet. Epidemiol. 17(Suppl. 1), S379-S384 (1999).
183. Qian Q, Wang Y, Li J et al.: Evaluation of potential gene-gene interactions for attention deficit hyperactivity disorder in the Han Chinese population. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144, 200-2006 (2007).
184. Jonsson EG, Nothen MM, Grunhage F et al.: Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol. Psychiatry 4, 290-296 (1999).
185. Pohjalainen T, Rinne JO, Nagren K et al.: The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol. Psychiatry 3, 256-260 (1998).
186. Ritchie T, Noble EP: Association of seven polymorphisms of the D2 dopamine receptor gene with brain receptor-binding characteristics. Neurochem. Res. 28, 73-82 (2003).
187. Thompson J, Thomas N, Singleton A et al.: D2 dopamine receptor gene (DRD2) Taq1 polymorphism A: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 7, 479-484 (1997).
188. Laruelle M, Gelernter J, Innis RB: D2 receptors binding potential is not affected by Taq1 polymorphism at the D2 receptor gene. Mol. Psychiatry 3, 261-265 (1998).
189. Blum K, Sheridan PJ, Wood RC, Braverman ER, Chen TJ, Comings DE: Dopamine D2 receptor gene variants: association and linkage studies in impulsive-addictive-compulsive behaviour. Pharmacogenetics 5, 121-141 (1995).
190. Duan J, Wainwright MS, Comeron JM et al.: Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum. Mol. Genet. 12, 205-216 (2003).
191. Dean A: On a chromosome far, far away: LCRs and gene expression. Trends Genet. 22, 38-45 (2006).
192. Barr CL, Wigg KG, Wu J et al.: Linkage study of two polymorphisms at the dopamine D3 receptor gene and attention-deficit hyperactivity disorder. Am. J. Med. Genet. 96, 114-117 (2000).
193. Muglia P, Jain U, Kennedy JL: A transmission. disequilibrium test of the Ser9/Gly dopamine D3 receptor gene polymorphism in adult attention-deficit hyperactivity disorder. Behav. Brain Res. 130, 91-95 (2002).
194. Guan L, Wang B, Chen Y et al.: A high-density single-nucleotide polymorphism screen of 23 candidate genes in attention deficit hyperactivity disorder: suggesting multiple susceptibility genes among Chinese Han population. Mol. Psychiatry DOI: 10.1038/sj.mp.4002139 (2008).
195. Hawi Z, Foley D, Kirley A, McCarron M, Fitzgerald M, Gill M: Dopa decarboxylase gene polymorphisms and attention deficit hyperactivity disorder (ADHD): no evidence for association in the Irish population. Mol. Psychiatry 6, 420-424 (2001).
196. Ribases M, Ramos-Quiroga JA, Hervas A et al.: Exploration of 19 serotoninergic candidate genes in adults and children with attention-deficit/hyperactivity disorder identifies association for 5HT2A, DDC and MAOB. Mol. Psychiatry DOI: 10.1038/sj.mp.4002100 (2007).
197. Albanese V, Biguet NF, Kiefer H, Bayard E, Mallet J, Meloni R: Quantitative effects on gene silencing by allelic variation at a tetranucleotide microsatellite. Hum. Mol. Genet. 10, 1785-1792 (2001).
198. Eisenberg J, Mei-Tal G, Steinberg A et al.: Haplotype relative risk study of catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD): association of the high-enzyme activity Val allele with ADHD impulsive-hyperactive phenotype. Am. J. Med. Genet. 88, 497-502 (1999).
199. Manor I, Kotler M, Sever Y et al.: Failure to replicate an association between the catechol-O-methyltransferase polymorphism and attention deficit hyperactivity disorder in a second, independently recruited Israeli cohort. Am. J. Med. Genet. 96, 858-860 (2000).
200. Lotta T, Vidgren J, Tilgmann C et al.: Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 34, 4202-4210 (1995).
201. Lachman HM, Morrow B, Shprintzen R et al.: Association of codon 108/158 catechol-O-methyltransferase gene polymorphism with the psychiatric manifestations of velo-cardio-facial syndrome. Am. J. Med. Genet. 67, 468-472 (1996).
202. Barr CL, Wigg K, Malone M et al.: Linkage study of catechol-O-methyltransferase and attention-deficit hyperactivity disorder. Am. J. Med. Genet. 88, 710-713 (1999).
203. Hawi Z, Millar N, Daly G, Fitzgerald M, Gill M: No association between catechol-O-methyltransferase (COMT) gene polymorphism and attention deficit hyperactivity disorder (ADHD) in an Irish simple. Am. J. Med. Genet. 96, 282-284 (2000).
204. Turk D, Williams H, Langley-K, Owen M, Thapar A, O'Donovan MC: A family based study of catechol-O-methyltransferase (COMT) and attention deficit hyperactivity disorder (ADHD). Am. J. Med. Genet. B Neuropsychiatr. Genet. 133, 64-67 (2005).
205. Taerk E, Grizenko N, Ben Amor L et al.: Catechol-O-methyltransferase (COMT) Val108/158 Met polymorphism does not modulate executive function in children with ADHD. BMC Med. Genet. 5, 30 (2004).
206. Bellgrove MA, Domschke K, Hawi Z et al.: The methionine allele of the COMT polymorphism impairs prefrontal cognition in children and adolescents with ADHD. Exp. Brain Res. 163, 352-360 (2005).
207. Cheuk DK, Wong V: Meta-analysis of association between a catechol-O-methyltransferase gene polymorphism and attention deficit hyperactivity disorder. Behav. Genet. 36, 651-659 (2006).
208. Bray NJ, Buckland PR, Williams NM et al.: A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am. J. Hum. Genet. 73, 152-161 (2003).
209. Craddock N, Owen MJ, O'Donovan MC: The catechol-O-methyl transferase (COMT) gene as a candidate for psychiatric phenotypes: evidence and lessons. Mol. Psychiatry 11, 446-458 (2006).
210. Comings DE, Gade-Andavolu R, Gonzalez N, Blake H, Wu S, MacMurray JP: Additive effect of three noradrenergic genes (ADRA2a, ADRA2C, DBH) on attention-deficit hyperactivity disorder and learning disabilities in Tourette syndrome subjects. Clin. Genet. 55, 160-172 (1999).
211. Roman T, Schmitz M, Polanczyk GV, Eizirik M, Rohde LA, Hutz MH: Further evidence for the association between attention-delicit/hyperactivity disorder and the dopamine-β-hydroxylase gene. Am. J. Med. Genet. 114, 154-158 (2002).
212. Wigg K, Zai G, Schachar R et al.: Attention deficit hyperactivity disorder and the gene for dopamine β-hydroxylase. Am. J. Psychiatry 159, 1046-1048 (2002).
213. Bhaduri N, Mukhopadhyay K: Lack of significant association between -1021C->T polymorphism in the dopamine β-hydroxylase gene and attention deficit hyperactivity disorder. Neurosci. Lett. 402, 12-16 (2006).
214. Inkster B, Muglia P, Jain U, Kennedy JL: Linkage disequilibrium analysis of the dopamine β-hydroxylase gene in persistent attention deficit hyperactivity disorder. Psychiatr. Genet. 14, 117-120 (2004).
215. Cubells JF, Zabetian CP: Human genetics of plasma dopamine β-hydroxylase activity: applications to research in psychiatry and neurology. Psychopharmacology (Berl.) 174, 463-476 (2004).
216. Wei J, Ramchand CN, Hemmings GP: Possible control of dopamine β-hydroxylase via a codominant mechanism associated with the polymorphic (GT)n repeat at its gene locus in healthy individuals. Hum. Genet. 99, 52-55 (1997).
217. Cubells JF, Kranzler HR, McCance-Katz E et al.: A haplotype at the DBH locus, associated with low plasma dopamine β-hydroxylase activity, also associates with cocaine-induced paranoia. Mol. Psychiatry 5, 56-63 (2000).
218. Tang Y, Buxbaum SG, Waldman I et al.: A single nucleotide polymorphism at DBH, possibly associated with attention-deficit/ hyperactivity disorder, associates with lower plasma dopamine beta-hydroxylase activity and is in linkage disequilibrium with two putative functional single nucleotide polymorphisms. Biol. Psychiatry 60, 1034-1038 (2006).
219. Hotamisligil GS, Breakefield XO: Human monoamine oxidase A gene determines levels of enzyme aprivity. Am. J. Hum. Genet. 49, 383-392 (1991).
220. Sabol SZ, Hu S, Hamer D: A functional polymorphism in the monoamine oxidase A gene promoter. Hum. Genet. 103, 273-279 (1998).
221. Deckert J, Catalano M, Syagailo YV et al.: Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum. Mol. Genet. 8, 621-624 (1999).
222. Denney RM, Koch H, Craig IW: Association between monoamine oxidase A activity in human male skin fibroblasts and genotype of the MAOA promoter-associated variable number tandem repeat. Hum. Genet. 105, 542-551 (1999).
223. Balciuniene J, Emilsson L, Oreland L, Pettersson U, Jazin E: Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Hum. Genet. 110, 1-7 (2002).
224. Jiang S, Xin R, Wu X et al.: Association between attention deficit hyperactivity disorder and the DXS7 locus. Am. J. Med. Genet. 96, 289-292 (2000).
225. Lowe N, Hawi Z, Fitzgerald M, Gill M: No evidence of linkage or association between ADHD and DXS7 locus in Irish population. Am. J. Med. Genet. 105, 394-395 (2001).
226. Jiang S, Xin R, Lin S et al.: Linkage studies between attention-deficit hyperactivity disorder and the monoamine oxidase genes. Am. J. Med. Genet. 105, 783-788 (2001).
227. Manor I, Tyano S, Mel E et al.: Family-based and association studies of monoamine oxidase A and attention deficit hyperactivity disorder (ADHD): preferential transmission of the long promoter-region repeat and its association with impaired performance on a continuous performance test (TOVA). Mol. Psychiatry 7, 626-632 (2002).
228. Das M, Bhowmik AD, Sinha S et al.: MAOA promoter polymorphism and attention deficit hyperactivity disorder (ADHD) in indian children. Am. J. Med. Genet. B Neuropsychiatr. Genet. 141, 637-642 (2006).
229. Lawson DC, Turic D, Langley K et al.: Association analysis of monoamine oxidase A and attention deficit hyperactivity disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 116, 84-89 (2003).
230. Manuck SB, Flory JD, Ferrell RE, Mann JJ, Muldoon MF: A regulatory polymorphism of the monoamine oxidase-A gene may be associated with variability in aggression, impulsivity, and central nervous system serotonergic responsivity. Psychiatry Res. 95, 9-23 (2000).
231. Domschke K, Sheehan K, Lowe N et al.: Association analysis of the monoamine oxidase A and B genes with attention deficit hyperactivity disorder (ADHD) in an Irish sample: preferential transmission of the MAO-A 941G allele to affected children. Am. J. Med. Genet. B Neuropsychiatr. Genet. 134, 110-114 (2005).
232. Xu X, Brookes K, Chen CK, Huang YS, Wu YY, Asherson P: Association study between the monoamine oxidase A gene and attention deficit hyperactivity disorder in Taiwanese samples. BMC Psychiatry 7, 10 (2007).
233. Fowler JS, Alia-Klein N, Kriplani A et al.: Evidence that brain MAO A activity does not correspond to MAO A genotype in healthy male subjects. Biol. Psychiatry 62, 355-358 (2007).
234. Garpenstrand H, Ekblom J, Forslund K, Rylander G, Oreland L: Platelet monoamine oxidase activity is related to MAOB intron 13 genotype. J. Neural Transm. 107, 523-530 (2000).
235. Ekblom J, Garpenstrand H, Damberg M, Chen K, Shih JC, Oreland L: Transcription factor binding to the core promoter of the human monoamine oxidase B gene in the cerebral cortex and in blood cells. Neurosci. Lett. 258, 101-104 (1998).
236. Winblad B, Gottfries CG, Oreland L, Wiberg A: Monoamine oxidase in platelets and brains of non-psychiatric and non-neurological geriatric patients. Med. Biol. 57, 129-132 (1979).
237. Young WF Jr., Laws ER Jr., Sharbrough FW, Weinshilboum RM: Human monoamine oxidase. Lack of brain and platelet correlation. Arch. Gen. Psychiatry 43, 604-609 (1986).
238. Li J, Wang Y, Hu S et al.: The monoamine oxidase B gene exhibits significant association to ADHD. Am. J. Med. Genet. B Neuropsychiatr. Genet. 147, 370-374 (2008).
239. Barr CL, Feng Y, Wigg K et al.: Identification of DNA variants in the SNAP-25 gene and linkage study of these polymorphisms and attention-deficit hyperactivity disorder. Mol. Psychiatry 5, 405-409 (2000).
240. Feng Y, Crosbie J, Wigg K et al.: The SNAP25 gene as a susceptibility gene contributing to attention-deficit hyperactivity disorder. Mol. Psychiatry 10, 998-1005, 973 (2005).
241. Mill J, Curran S, Kent L et al.: Association study of a SNAP-25 microsatellite and attention deficit hyperactivity disorder. Am. J. Med. Genet. 114, 269-271 (2002).
242. Mill J, Richards S, Knight J, Curran S, Taylor E, Asherson P: Haplotype analysis of SNAP-25 suggests a role in the aetiology of ADHD. Mol. Psychiatry 9, 801-810 (2004).
243. Kustanovich V, Merriman B, McGough J, McCracken JT, Smalley SL, Nelson SF: Biased paternal transmission of SNAP-25 risk alleles in attention-deficit hyperactivity disorder. Mol. Psychiatry 8, 309-315 (2003).
244. Brophy K, Hawi Z, Kirley A, Fitzgerald M, Gill M: Synaptosomal-associated protein 25 (SNAP-25) and attention deficit hyperactivity disorder (ADHD): evidence of linkage and association in the Irish population. Mol. Psychiatry 7, 913-917 (2002).
245. Brookes K, Xu X, Chen W et al.: The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: association signals in DRD4, DAT1 and 16 other genes. Mol. Psychiatry 11, 934-953 (2006).
246. Choi TK, Lee HS, Kim JW et al.: Support for the MnlI polymorphism of SNAP25; a Korean ADHD case-control study. Mol. Psychiatry 12, 224-226 (2007).
247. Kim JW, Biederman J, Arbeitman L et al.: Investigation of variation in SNAP-25 and ADHD and relationship to co-morbid major depressive disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 144B, 781-790 (2007).
248. Mill J, Xu X, Ronald A et al.: Quantitative trait locus analysis of candidate gene alleles associated with attention deficit hyperactivity disorder (ADHD) in five genes: DRD4, DAT1, DRD5, SNAP-25, and 5HT1B. Am. J. Med. Genet. B Neuropsychiatr. Genet. 133, 68-73 (2005).
249. Renner TJ, Walitza S, Dempfle A et al.: Allelic variants of SNAP25 in a family-based sample of ADHD. J. Neural Transm. 115, 317-321 (2008).
250. Brookes KJ, Knight J, Xu X, Asherson P: DNA pooling analysis of ADHD and genes regulating vesicle release of neurotransmitters. Am. J. Med. Genet. B Neuropsychiatr. Genet. 139, 33-37 (2005).
251. Dickman DK, Horne JA, Meinertzhagen IA, Schwarz TL: A slowed classical pathway rather than kiss-and-run mediates endocytosis at synapses lacking synaptojanin and endophilin. Cell 123, 521-533 (2005).
252. Laurin N, Misener VL, Crosbie J et al.: Association of the calcyon gene (DRD1IP) with attention deficit/hyperactivity disorder. Mol. Psychiatry 10, 1117-1125 (2005).
253. Turic D, Langley K, Kirov G, Owen MJ, Thapar A, O'Donovan MC: Direct analysis of the genes encoding G proteins G α T2, G α o, G α Z in ADHD. Am. J. Med. Genet. B Neuropsychiatr. Genet. 127, 68-72 (2004).
254. Laurin N, Ickowicz A, Pathare T et al.: Investigation of the G protein subunit Gα(olf) gene (GNAL) in attention deficit/ hyperactivity disorder. J. Psychiatr. Res. 42, 117-124 (2008).
255. Gershon ES, Badner JA, Detera-Wadleigh SD, Ferraro TN, Berrettini WH: Maternal inheritance and chromosome 18 allele sharing in unilineal bipolar illness pedigrees. Am. J. Med. Genet. 67, 202-207 (1996).
256. Nothen MM, Cichon S, Rohleder H et al.: Evaluation of linkage of bipolar affective disorder to chromosome 18 in a sample of 57 German families. Mol. Psychiatry 4, 76-84 (1999).
257. Stine OC, Xu J, Koskela R et al.: Evidence for linkage of bipolar disorder to chromosome 18 with a parent-of-origin effect. Am. J. Hum. Genet. 57, 1384-1394 (1995).
258. Chang FM, Kidd JR, Livak KJ, Pakstis AJ, Kidd KK: The world-wide distribution of allele frequencies at the human dopamine D4 receptor locus. Hum. Genet. 98, 91-101 (1996).
259. Barr CL, Kidd KK: Population frequencies of the A1 allele at the dopamine D2 receptor locus. Biol. Psychiatry 34, 204-209 (1993).
260. Washbourne P, Thompson PM, Carta M et al.: Genetic ablation of the t-SNARE SNAP-25 distinguishes mechanisms of neuroexocytosis. Nat. Neurosci. 5, 19-26 (2002).
261. Threlkeld SW, McChire MM, Bai J et al.: Developmental disruptions and behavioral impairments in rats following in utero RNAi of Dyx1c1. Brain Res. Bull. 71, 508-514 (2007).
262. Ramus F: Genes, brain, and cognition: a roadmap for the cognitive scientist. Cognition 101, 247-269 (2006).
263. Schulte-Korne G, Deimel W, Bartling J, Remschmidt H: Pre-attentive processing of auditory patterns in dyslexic human subjects. Neurosci. Lett. 276, 41-44 (1999).
264. Tallal P, Miller SL, Bedi G et al.: Language comprehension in language-learning impaired children improved with acoustically modified speech. Science 271, 81-84 (1996).
265. Strehlow U, Haffner J, Bischof J, Gratzka V, Parzer P, Resch F: Does successful training of temporal processing of sound and phoneme stimuli improve reading and spelling? Eur. Child Adolesc. Psychiatry 15, 19-29 (2006).
266. Kujala T, Karma K, Ceponiene R et al.: Plastic neural changes and reading improvement caused by audiovisual training in reading-impaired children. Proc. Natl Acad. Sci. USA. 98, 10509-105014 (2001).
267. Drysdale CM, McGraw DW, Stack CB et al.: Complex promoter and coding region β 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl Acad. Sci. USA 97, 10483-10488 (2000).
268. Jais PH: How frequent is altered gene expression among susceptibility genes to human complex disorders? Genet. Med. 7, 83-96 (2005).
269. Knight JC: Regulatory polymorphisms underlying complex disease traits. J. Mol. Med. 83, 97-109 (2005).
270. Buckland PR, Hoogendoorn B, Coleman SL, Guy CA, Smith SK, O'Donovan MC: Strong bias in the location of functional promoter polymorphisms. Hum. Mutat. 26, 214-223 (2005).
271. Buckland PR, Hoogendoorn B, Guy CA et al.: A high proportion of polymorphisms in the promoters of brain expressed genes influences transcriptional activity. Biochim. Biophys. Acta 1690, 238-249 (2004).
272. Rockman MV, Wray GA: Abundant raw material for cis-regulatory evolution in humans. Mol. Biol. Evol. 19, 1991-2004 (2002).
273. Heintzman ND, Stuarr-RK, Hon G et al.: Distinct and predictive, chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet. 39, 311-318 (2007).
274. Ni Z, Abou El Hassan M, Xu Z, Yu T, Bremner R: The chromatin-remodeling. enzyme BRG1 coordinates CIITA induction through many interdependent distal enhancers. Nat. Immunol. 9, 785-793 (2008).
275. Harold D, Paracchini S, Scerri T et al.: Further evidence that the KIAA0319 gene confers susceptibility to developmental dyslexia. Mol. Psychiatry 11, 1085-1091, 1061 (2006).
276. Deffenbacher KE, Kenyon JB, Hoover DM et al.: Refinement of the 6p21.3 quantitative trait locus influencing dyslexia: linkage and association analyses. Hum. Genet. 115, 128-138 (2004).
277. Francks C, Paracchini S, Smith SD et al.: A 77-kilobase region of chromosome 6p22.2 is associated with dyslexia in families from the United Kingdom and from the United States. Am. J. Hum. Genet. 75, 1046-1058 (2004).
278. Cope N, Harold D, Hill G et al.: Strong evidence that KIAA0319 on chromosome 6p is a susceptibility gene for developmental dyslexia. Am. J. Hum. Genet. 76, 581-5831 (2005).
279. Kaplan DE, Gayan J, Ahn J et al.: Evidence for linkage and association with reading disability on 6p21.3-22. Am. J. Hum. Genet. 70, 1287-1298 (2002).
280. Luciano M, Lind PA, Duffy DL et al.: A haplotype spanning KIAA0319 and TTRAP is associated with normal variation in reading and spelling ability. Biol. Psychiatry 62(7), 811-817 (2007).
281. Milberger S, Biederman J, Faraone SV, Guite J, Tsuang MT: Pregnancy, delivery and infancy complications and attention deficit hyperactivity disorder: issues of gene-environment interaction. Biol. Psychiatry 41, 65-75 (1997).
282. Ernst M, Moolchan ET, Robinson ML: Behavioral and neural consequences of prenatal exposure to nicotine. J. Am. Acad. Child. Adolesc. Psychiatry 40, 630-641 (2001).
283. Linnet KM, Dalsgaard S, Obel C et al.: Maternal lifestyle factors in pregnancy risk of attention deficit hyperactivity disorder and associated behaviors: review of the current evidence. Am. J. Psychiatry 160, 1028-1040 (2003).
284. Braun JM, Kahn RS, Froehlich T, Auinger P, Lanphear BP: Exposures to environmental toxicants and attention deficit hyperactivity disorder in U.S. children. Environ. Health Perspect. 114, 1904-1909 (2006).
285. Barman SK, Pulkkinen L, Kaprio J, Rose RJ: Inattentiveness, parental smoking and adolescent smoking initiation. Addiction 99, 1049-1061 (2004).
286. Batstra L, M Hadders-Algra, Neeleman J: Effect of antenatal exposure to maternal smoking on behavioural problems and academic achievement in childhood: prospective evidence from a Dutch birth cohort. Early Hum. Dev. 75, 21-33 (2003).
287. Kotimaa AJ, Moilanen I, Taanila A et al.: Maternal smoking and hyperactivity in 8-year-old children. J. Am. Acad. Child. Adolesc. Psychiatry 42, 826-833 (2003).
288. Thapar A, Fowler T, Rice F et al.: Maternal smoking during pregnancy and attention deficit hyperactivity disorder symptoms in offspring. Am. J. Psychiatry 160, 1985-1989 (2003).
289. Mick E, Biederman J, Faraone SV, Sayer J, Kleinman S: Case-control study of attention-deficit hyperactivity disorder and maternal smoking, alcohol use, and drug use during pregnancy. J. Am. Acad. Child. Adolesc. Psychiatry 41, 378-385 (2002).
290. Sprich-Buckminster S, Biederman J, Milberger S, Faraone SV, Lehman BK: Are perinatal complications relevant to the manifestation of ADD? Issues of comorbidity and familiality. J. Am. Acad. Child. Adolesc. Psychiatry 32, 1032-1037 (1993).
291. Weissman MM, Warner V, Wickramaratne PJ, Kandel DB: Maternal smoking during pregnancy and psychopathology in offspring followed to adulthood. J. Am. Acad. Child. Adolesc. Psychiatry. 38, 892-899 (1999).
292. Thapar A, Langley K, Fowler T et al.: Catechol O-methyltransferase gene variant and birth weight predict early-onset antisocial behavior in children with attention-deficit/ hyperactivity disorder. Arch. Gen. Psychiatry 62, 1275-1278 (2005).
293. Laucht M, Skowronek MH, Becker K et al.: Interacting effects of the dopamine transporter gene and psychosocial adversity on attention-deficit/hyperactivity disorder symptoms among 15-year-olds from a high-risk community sample. Arch. Gen. Psychiatry 64, 585-590 (2007).
294. Neuman RJ, Lobos E, Reich W, Henderson CA, Sun LW, Todd RD: Prenatal smoking exposure and dopaminergic genotypes interact to cause a severe ADHD subtype. Biol. Psychiatry 61, 1320-1328 (2007).
295. Knopik VS, Sparrow EP, Madden PA et al.: Contributions of parental alcoholism, prenatal substance exposure, and genetic transmission to child ADHD risk: a female twin study. Psychol. Med. 35, 625-635 (2005).
296. Gross J, Muller I, Chen Y et al.: Perinatal asphyxia induces region-specific long-term changes in mRNA levels of tyrosine hydroxylase and dopamine D(1) and D(2) receptors in rat brain. Brain Res. Mol. Brain Res. 79, 110-117 (2000).
297. Rommelse NN, Arias-Vasquez A, Altink ME et al.: Neuropsychological endophenotype approach to genome-wide linkage analysis identifies susceptibility loci for ADHD on 2q21.1 and 13q12.11. Am. J. Hum. Genet. 83, 99-105 (2008).
298. Kuntsi J, Neale BM, Chen W, Faraone SV, Asherson P: The IMAGE project: methodological issues for the molecular genetic analysis of ADHD. Behav. Brain Funct. 2, 27 (2006).
299. Bellgrove MA, Mattingley JB: Molecular genetics of attention. Ann. NY Acad. Sci. 1129, 200-212 (2008).
300. Waldman ID: Statistical approaches to complex phenotypes: evaluating neuropsychological endophenotypes for attention-deficit/hyperactivity disorder. Biol. Psychiatry 57, 1347-1356 (2005).